Labcorp (LH) announced it will offer the Elecsys pTau181 test, the only blood test cleared by the U.S. FDA to aid in the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary-care setting. Developed by Roche Diagnostics (RHHBY), Labcorp plans to make the test available nationwide by early 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH: